#ASH24: Kura Oncology details ‘aggressive’ approach in first-line AMLnews2024-12-10T02:16:05+00:00December 10th, 2024|Endpoints News|
#ASH24: Retrospective analysis shows potential for GLP-1s to treat blood clotsnews2024-12-10T02:08:33+00:00December 10th, 2024|Endpoints News|
#ASH24: GSK reports Blenrep overall survival data in multiple myeloma as it plots market reentrynews2024-12-09T18:30:55+00:00December 9th, 2024|Endpoints News|
ICER finds Vertex’s non-opioid pain treatment could bring cost savings at a lower pricenews2024-12-09T17:04:16+00:00December 9th, 2024|Endpoints News|
#ASH24: AbbVie, Genmab tout Epkinly combinations in earlier lines of non-Hodgkin lymphomanews2024-12-09T17:00:09+00:00December 9th, 2024|Endpoints News|
AbbVie declares third Phase 3 Parkinson’s win from Cerevel takeovernews2024-12-09T16:15:20+00:00December 9th, 2024|Endpoints News|
Merck’s Keytruda combo misses overall survival in Phase 3 trial in ovarian cancernews2024-12-09T15:47:18+00:00December 9th, 2024|Endpoints News|
#ASH24: Beam shares results from seven patients who received gene-edited sickle cell therapynews2024-12-09T03:10:43+00:00December 9th, 2024|Endpoints News|
#ASH24: AstraZeneca outlines Phase 1 data for CD19 bispecific T cell engager from TeneoTwo buyoutnews2024-12-09T00:37:21+00:00December 9th, 2024|Endpoints News|
BioAge Labs scraps Phase 2 obesity trial just months after IPOnews2024-12-06T22:32:41+00:00December 6th, 2024|Endpoints News|
